Starling Oncology Institute (STLN) Stock Statistics & Valuation Metrics

Starling Oncology Institute has a market cap or net worth of $624.89M. The enterprise value is $622.84M.

Market Cap

$624.89M

Enterprise Value

$622.84M

Starling Oncology Institute has 99,982,930 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

99,982,930

Owned by Insiders

21.39%

Owned by Institutions

17.11%

Starling Oncology Institute’s return on equity (ROE) is 3.86 and return on invested capital (ROIC) is -35.70%.

Return on Equity (ROE)

3.86

Return on Assets (ROA)

-0.37

Return on Invested Capital (ROIC)

-35.70%

Return on Capital Employed (ROCE)

-0.39

Revenue Per Employee

784.29K

Profits Per Employee

-94.55K

Employee Count

641

Asset Turnover

3.05

Inventory Turnover

25.26

The current PE Ratio of Starling Oncology Institute is -21.13. Starling Oncology Institute’s PEG ratio is 0.31.

PE Ratio

-21.13

PS Ratio

1.08

PB Ratio

-26.22

Price to FCF

-192.91

Price to Operating Cash Flow

1991.52

PEG Ratio

0.31

In the last 12 months, Starling Oncology Institute had revenue of 502.73M and earned -60.61M in profits. Earnings per share was -0.54.

Revenue

502.73M

Gross Profit

76.44M

Operating Income

-36.08M

Pretax Income

-60.74M

Net Income

-60.61M

EBITDA

-42.52M

Earnings Per Share (EPS)

-0.54

In the last 12 months, operating cash flow was 328.00K and capital expenditures -3.61M, giving a free cash flow of -3.29M billion.

Operating Cash Flow

328.00K

Free Cash Flow

-3.29M

Free Cash Flow per Share

-0.03

Starling Oncology Institute pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-0.52%

Earnings Yield

-5.56%

Beta

2.11

52-Week Price Change

41.20%

50-Day Moving Average

6.46

200-Day Moving Average

4.71

Relative Strength Index (RSI)

46.35

Average Volume (3m)

1.37M

Starling Oncology Institute upcoming earnings date is Nov 05, 2026, After Close (Not Confirmed).

Last Earnings Date

Aug 06, 2026

Next Earnings Date

Nov 05, 2026

Ex-Dividend Date

―

Starling Oncology Institute as a current ratio of 1.59, with Debt / Equity ratio of -659.59%

Current Ratio

1.59

Quick Ratio

1.35

Debt to Market Cap

0.14

Net Debt to EBITDA

-1.65

Interest Coverage Ratio

-3.20

In the past 12 months, Starling Oncology Institute has paid -131.00K in taxes.

Income Tax

-131.00K

Effective Tax Rate

0.00

Starling Oncology Institute EV to EBITDA ratio is -31.90, with an EV/FCF ratio of -212.20.

EV to Sales

1.19

EV to EBITDA

-31.90

EV to Free Cash Flow

-212.20

EV to Operating Cash Flow

2125.83

Starling Oncology Institute has $41.09M in cash and marketable securities with $104.48M in debt, giving a net cash position of -$63.38M billion.

Cash & Marketable Securities

$41.09M

Total Debt

$104.48M

Net Cash

-$63.38M

Net Cash Per Share

-$0.63

Tangible Book Value Per Share

-$0.41

Gross margin is 15.69%, with operating margin of -4.44%, and net profit margin of -6.18%.

Gross Margin

15.69%

Operating Margin

-4.44%

Pretax Margin

-6.18%

Net Profit Margin

-6.18%

EBITDA Margin

-3.72%

EBIT Margin

-4.88%

The average price target for Starling Oncology Institute is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$10.00

Price Target Upside

57.73% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

38.38%

EPS Growth Forecast

54.91%

Smart Score

9

AI Score

57